Clinical Trials
212 trialsNCT07495579 2026-05-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07608458 2026-05-27
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
City of Hope Medical Center
Phase NA Not yet recruiting
NCT07600346 2026-05-20
A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery
The First Hospital of Jilin University
Not yet recruiting
NCT07111130 2026-05-15
RE-BALANCE
National Cancer Centre, Singapore
Phase NA Not yet recruiting
NCT07590336 2026-05-15
NYHCC
Peking Union Medical College Hospital
Phase 1/2 Not yet recruiting
NCT07586046 2026-05-14
MARGIN
Northwestern University
Phase 2 Not yet recruiting
NCT07582978 2026-05-13
PLVT_TH
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
NCT07583316 2026-05-13
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT07584018 2026-05-13
The DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07584317 2026-05-13
AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
Zhongda Hospital
Not yet recruiting
NCT07580261 2026-05-12
YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
West China Hospital
Phase 1 Not yet recruiting
NCT07582419 2026-05-12
HDL-CEUS-MRI
The First Hospital of Jilin University
Not yet recruiting
NCT07226063 2026-05-05
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07568457 2026-05-05
Social Determinants of Health HCC Trial
University of Southern California
Phase NA Not yet recruiting
NCT07565415 2026-05-04
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT04172779 2026-05-01
ECHO-B
University of Texas Southwestern Medical Center
Phase 2 Not yet recruiting
NCT07557914 2026-04-30
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT07558200 2026-04-30
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1 Not yet recruiting
NCT07556835 2026-04-29
BILIVER
Azienda USL Toscana Centro
Not yet recruiting
NCT07543783 2026-04-28
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07553767 2026-04-28
Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
Ningbo No.2 Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07547553 2026-04-23
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Huahui Health
Phase 1/2 Not yet recruiting
NCT07543510 2026-04-22
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT07544121 2026-04-22
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
Nanfang Hospital, Southern Medical University
Phase NA Not yet recruiting
NCT07487402 2026-04-21
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT07535840 2026-04-17
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Phase NA Not yet recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537946 2026-04-17
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT07537959 2026-04-17
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
Tongji Hospital
Phase NA Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT07515469 2026-04-07
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT06971848 2026-03-30
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT07495735 2026-03-27
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
First Affiliated Hospital of Wenzhou Medical University
Not yet recruiting
NCT07365839 2026-03-25
CLeAR
Virginia Commonwealth University
Phase 1 Not yet recruiting
NCT07489768 2026-03-24
CCGLC-019
Tongji Hospital
Not yet recruiting
NCT07483359 2026-03-19
CONV3RSION
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT07479485 2026-03-18
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Lepu Biopharma Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07481032 2026-03-18
Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study
Nanfang Hospital, Southern Medical University
Phase NA Not yet recruiting
NCT07475026 2026-03-16
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT07436988 2026-03-12
ReLIVE
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 1 Not yet recruiting
NCT07466225 2026-03-12
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
Peking University
Not yet recruiting
NCT07381634 2026-03-11
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07463248 2026-03-11
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT07461675 2026-03-10
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland
Phase 3 Not yet recruiting
NCT07446257 2026-03-03
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Not yet recruiting